Skip to main content
Lyrea avatar

Not yet reviewed — this article is pending editorial review by Lyrea.

Citation noticeOur citation system is being overhauled

References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.

Rilmazafone

This article is a stubmissing:
Subjective Effects
Pharmacology
Interactions
Tolerance
History & Culture
Rilmazafone molecule structureRilmazafone molecule structure
Chemical Class
1,4-Benzodiazepine

Dosage & Duration

Dosage

Doses are population estimates that vary widely between individuals.

Threshold~0.5 mg
Light0.5-1 mg
Moderate1-2 mg
Strong2-4 mg
Heavy4+ mg

Duration

Onset30-60 minutes
After Effects6-12 hours
Total6-8 hours

Subjective Effects

Subjective Effects not written up yet

Pharmacology

Pharmacology not written up yet

Interactions

Interactions not written up yet

An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.

Check TripSit

Tolerance

Tolerance not written up yet

Harm Potential

Addiction & Dependence

Psychological

Moderate

The extracted TripSit quote classifies rilmazafone as habit-forming.

Toxicity

central nervous system

Amnesia and dystaxia are listed as adverse effects.

History & Culture

History & Culture not written up yet

Legality

By Country

Prescription1
Japan flagJapanPrescription only

References

Citations

  1. 医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律第四十九条第一項の規定に基づき厚生労働大臣の指定する医薬品 (平成17年厚生労働省告示第24号), item 8(1221). mhlw.go.jp (n.d.). https://www.mhlw.go.jp/web/t_doc?dataId=81aa6750&dataType=01
  2. 医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律 (昭和35年法律第145号), Article 49. mhlw.go.jp (n.d.). https://www.mhlw.go.jp/web/t_doc?dataId=81004000&dataType=01
  3. リスミー錠1mg／リスミー錠2mg 添付文書 (2025年4月改訂, 第2版). pmda.go.jp (n.d.). https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/672173_1129006F1021_3_041

Article Status

  • Josie Kins avatar
    Step 1 · Automated synthesis

    An autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.

  • Step 2 · First-pass reviewPending

    Not yet reviewed — this article is pending editorial review by Lyrea.

  • Step 3 · Citation reviewPending

    No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.

Recent changes7 human edits · latest

Times are UTCNewest first

24 January 2026

  1. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  2. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  3. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  4. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  5. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  6. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  7. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

All changes to this article · Site-wide recent changes

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the Rilmazafone article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.